Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 54 Publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MlS4T4lv[XOnIFHzd4F6 NED5UIpKdmirYnn0bY9vKG:oIGDES2YucW6mdXPl[EBDemSXIHnuZ49zeG:{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= Ml6zNVI3PDZyMUm=
3T3 M3vaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPHflVbUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=> NX7xfHBTOTJ4NE[wNVk>
3T3 NHPmR41HfW6ldHnvckBCe3OjeR?= NIj5dYFKdmirYnn0bY9vKG:oIG\hd4N2dGG{IHXu[I91cGWuaXHsJIdzd3e2aDDmZYN1d3JicnXj[ZB1d3Jid3n0bEBKSzVyIH;mJFAvODVizszN MYixNlY1PjBzOR?=
3T3 NGLsfIVMcW6jc3WgRZN{[Xl? M13hOFIxKG2rbh?= NWnWNoxpTE2VTx?= MX7D[YxtfWyjcjDpcohq[mm2aX;uJI9nKF[HR1[gbY5lfWOnZDDoeY1idiCNRGKgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB{MjFOwG0> MlTONVYyPjJyMEi=
NIH3T3 NXP2TZllU2mwYYPlJGF{e2G7 NYX0UFd6OjBibXnu NIf6e5hFVVOR MlXtbY5pcWKrdDDoeY1idiCNRGKgb4lv[XOnIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMUig{txO NVLEeopWOTZzNkKwNFg>
A549 MlvPSpVv[3Srb36gRZN{[Xl? MkLXSG1UVw>? MYXJcohq[mm2aX;uJI9nKGNvTXX0JIRmeGWwZHXueEBJT0ZvaX7keYNm\CCqdX3hckBCPTR7IHPlcIwhdWmpcnH0bY9vKHerdHigTWM2OCCxZjCyJO69VQ>? Mnj6NVg1OzRzNEW=
DU145 MXzGeY5kfGmxbjDBd5NigQ>? NVvlNmY4TE2VTx?= M1ft[mlvcGmkaYTpc44hd2ZiYz3N[ZQh\GWyZX7k[Y51KEiJRj3pcoR2[2WmIHj1cYFvKESXMUS1JINmdGxic3PheJRmemmwZzD3bZRpKEmFNUCgc4YhOTBizszN M3KwdFE5PDN2MUS1
KB3-1 MXnDfZRwfG:6aXOgRZN{[Xl? NUHzNXpVPzJiaB?= MUfEUXNQ MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> MYWxPVM6PzN{Mh?=
KBV1 MoXaR5l1d3SxeHnjJGF{e2G7 NV;RUlg1PzJiaB?= NHuwRpVFVVOR MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOge4l1cCCLQ{WwJI9nKDRwMTFOwG0> M{jFfFE6Ozl5M{Ky
A375 NVf6TlJsS3m2b4TvfIlkKEG|c3H5 NWnkbVE2PzJiaB?= NUXVTIRZTE2VTx?= NF3PU|lKSzVyPUWuOEDPxE1? NFHJWJIyQTZ3NESwPC=>
RS4-11 MXfGeY5kfGmxbjDBd5NigQ>? MoPVNkBp M2XZfGlvcGmkaYTpc44hd2ZiRlzUN{BifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQTlizszN Mn\BNVk3PTR2MEi=
RS4-11 MVvGeY5kfGmxbjDBd5NigQ>? NXjKT4lHOiCq MXrJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{PCEQvF2= NFzHVIsyQTZ3NESwPC=>
Sf9 NXn2WohKU2mwYYPlJGF{e2G7 M2\MVlMxKG2rbh?= NYjpfIhpUW6qaXLpeIlwdiCxZjDHV3QufGGpZ3XkJHZGT0[UIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zOEWg{txO MUexPVg2PDB3MR?=
Ba/F3 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXq3NkBp MXHJR|UxRTFwMjFOwG0> NF7wRlgzODFzN{CwOC=>
BaPTC2 M{DndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhO|IhcA>? MWPJR|UxRTBwMkKg{txO NVTn[XpMOjBzMUewNFQ>
Sf9 MV3GeY5kfGmxbjDBd5NigQ>? NHX0fVMyKGh? MoXQSG1UVw>? Ml7DTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? MV[yNFEyPzByNB?=
H4 NFvLfWZEgXSxdH;4bYMhSXO|YYm= Mn2xNVAh|ryP MXXUc5hq[2m2eTDpckBpfW2jbjDIOEBk\Wyucx?= NF3BWm4zODN3MEiwOi=>
SF-539 M{LqbWtqdmG|ZTDBd5NigQ>? MoiyN|M{KM7:TR?= NUezTJpvPjBibXnu NEPw[pRFVVOR NGnzU2ZKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEzNjJizszN NFPvTJUzODRyM{ewNC=>
U251 NFvpdoxMcW6jc3WgRZN{[Xl? NIjGZpA{OzNizszN NF7OXmg3OCCvaX6= NG\te3hFVVOR MYrJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDF6Lkmg{txO M2DRSVIxPDB|N{Cw
A431 M3XwSmtqdmG|ZTDBd5NigQ>? NETo[ZhKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDF{LkKg{txO M1zp[lIxPTV6MEey
A431 Ml25T4lv[XOnIFHzd4F6 MXzJcohq[mm2aX;uJI9nKF[HR1\SNkBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEG4Mlkh|ryP MortNlA2PThyN{K=
HepG2 NH63NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMZ|czKGh? NXHVS3NUUUN3ME2zMlgyKM7:TR?= MmLkNlA2PzB3Mk[=
Kasumi-1 NV3PVHdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm2eW44OiCq M{nGOWlEPTB;MD6wNVYh|ryP M3j1RlIxPTdyNUK2
RS4-11 M1\OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlryO|IhcA>? NYnlNGg{UUN3ME2xJO69VQ>? MmD1NlA2PzB3Mk[=
THP1 M1WzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS3NkBp M2XRTmlEPTB;MD61JO69VQ>? MWqyNFU4ODV{Nh?=
Kasumi-1 NIjQbHRHfW6ldHnvckBCe3OjeR?= NIj4fVdKdmirYnn0bY9vKG:oIHOtT4l1KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF3IN88US=> MlvONlA5OzNyM{m=
A549 NIDMVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDUlE3KGh? NGfrVlRCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzz MYmyNVQ2ODR4Mx?=
HL60 NVz4W5BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFd5VKOTZiaB?= MlmxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\Wyucx?= MmDNNlE1PTB2NkO=
HUVEC M3fQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xOkBp MlfzTY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iB{Lke1JO69VQ>? NHPib5EzOTR3MES2Ny=>
HUVEC NFPsUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7wVY1bOTZiaB?= MmLjTY5pcWKrdHnvckBw\iCkRlfGMYlv\HWlZXSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iB2LkC0JO69VQ>? NHe2NpozOTR3MES2Ny=>
IM9 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXjRnEyPiCq NULScXJvSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz MYKyNVQ2ODR4Mx?=
K562 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrMR|RNOTZiaB?= MXXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| M1Gz[lIyPDVyNE[z
MDA-MB-231 NI\Bc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxOkBp M1i0RWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN? MnvYNlE1PTB2NkO=
H460 M{PhPWN6fG:2b4jpZ{BCe3OjeR?= MlmyO|IhcA>? NI[2emNKSzVyPUKuO{DPxE1? M2f1S|IyPjJzOEiw
SMMC7721 MnqyR5l1d3SxeHnjJGF{e2G7 M4[0blczKGh? M2PQWmlEPTB;Nj60O{DPxE1? M37ETlIyPjJzOEiw
WI38 NHTCdlFEgXSxdH;4bYMhSXO|YYm= NHjicpk4OiCq MmfNTWM2OD16LkW2JO69VQ>? MUKyNVYzOTh6MB?=
HEK293 NXLvVpFSU2mwYYPlJGF{e2G7 MXSxNFAhdk1? MYGxJIg> MXTkc4V{KG6xdDDpcohq[mm2IG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIIT5do9{cW6nIEGxO|UhemW|aXT1[UBwdiCYRVfGVlIh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsdy=> NVz3dIRNOjF6OEWyPFc>
HUVEC MXXGeY5kfGmxbjDBd5NigQ>? MVqxJO69VQ>? MkLPNlQhcA>? NInzb4JCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCYRVfGMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25? NH3FeIIzOTl4M{OwOS=>
HUVEC M1zWSWZ2dmO2aX;uJGF{e2G7 MnzMNUDPxE1? MnnQNUBp MlT0TY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE NFW4V5EzOTl4M{OwOS=>
HUVEC M{X4XWZ2dmO2aX;uJGF{e2G7 NVHvUFV{OSEQvF2= MojDNUBp M2LlU2lvcGmkaYTpc44hd2ZiZV7PV{BxcG:|cHjvdplt[XSrb36gZZQhW2W{LUGxO|IhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD MYCyNVk3OzNyNR?=
HUVEC MVnLbY5ie2ViQYPzZZk> MkHINUDPxE1? M4Owc|EhcA>? MlrSTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIF1KHS7cj2xNVc2KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> NXOyTWZ{OjF7NkOzNFU>
HUVEC Mmm1SpVv[3Srb36gRZN{[Xl? M1;xdFEh|ryP M{TVelEhcA>? NWnyeGox\G:nczDuc5QhcW6qaXLpeEBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldk01PzNiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE NULlRW5lOjF7NkOzNFU>
HL60 NFu1e5JEgXSxdH;4bYMhSXO|YYm= M{DkTlUxKM7:TR?= NIjQUG81QCCq MkTCSG1UVw>? MnvlTWM2OD1zNT61JO69VQ>? M4HWcVIzODF7MUi4
K562 NHG4N|lEgXSxdH;4bYMhSXO|YYm= M1\OOFUxKM7:TR?= MV60PEBp M2HReGROW09? MYHJR|UxRTJzLkmg{txO NFXSfVUzOjBzOUG4PC=>
PC3 MkXqR5l1d3SxeHnjJGF{e2G7 M4LzPFUxKM7:TR?= M{XtWVQ5KGh? MkG3SG1UVw>? NUjOPGJpUUN3ME2yOU4yKM7:TR?= NVrVdXZLOjJyMUmxPFg>
SF-539 MkfqT4lv[XOnIFHzd4F6 NVjx[ZA6OzN|IN88US=> MkfXOlAhdWmw NWC5T3pFUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgeJlzd3OrbnWgb4lv[XOnIHHjeIl3cXS7IHnuJHBFT0ZvQlKtd5RqdXWuYYTl[EBpfW2jbjDTSk02OzliY3XscJMhf2m2aDDJR|UxKG:oIEGyMlIh|ryP NXTKZ4tnOjJ{MES3OFE>
HAEC NI[1SWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\oT4g1OTByIN88US=> MUi3NkBp MoT5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQVXDJINmdGy|IHX4dJJme3OrbnegWmVITlJid3n0bEBKSzVyIH;mJFAvOSEQvF2= M2rnV|IzPDR2Nke5
HT-29 NFfNUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNFAh|ryP MmfOO|IhcA>? NEniZ5JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwM{Og{txO NGLX[XMzOjR2NE[3PS=>
MV4-11 MnjGR5l1d3SxeHnjJGF{e2G7 MnnHO|IhcA>? NGnDO2lKSzVyPUCuNFA{KM7:TR?= NET4dJczOjR3MkWxPC=>
HepG2 NEHkNWNEgXSxdH;4bYMhSXO|YYm= NYDNVXNqPDhiaB?= MoLTTWM2OD1zMz6yOEDPxE1? M4LoRlIzPDh|NkC4
PC9 MlHtR5l1d3SxeHnjJGF{e2G7 NXfVe4d2PDhiaB?= NG\j[XlKSzVyPUGwMlk4KM7:TR?= Mnf4NlI1QDN4MEi=
CAKI-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNFAh|ryP M3jl[|Q5KGh? NV7vTXc3TE2VTx?= Ml25S2k2OD1yLk[zJO69VQ>? M2LyPFIzPTZyNkK3
EKVX NF3kbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrFdnIyODBizszN NYm0ZWlVPDhiaB?= M{XaXGROW09? MYXHTVUxRTdwOTFOwG0> MornNlI2PjB4Mke=
MCF7 NUPsXVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNFAh|ryP NFfRRWg1QCCq M3HBSmROW09? MkDzS2k2OT1{IN88US=> M17aWVIzPTZyNkK3
MDA-MB-435 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNFAh|ryP M2P5bFQ5KGh? MVPEUXNQ M1e2cmdKPTJ;MjFOwG0> NXrl[JlXOjJ3NkC2Nlc>
OVCAR3 M1;lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7KNVAxKM7:TR?= NG[1XFg1QCCq MXrEUXNQ Ml;vS2k2Oz1|LkKg{txO NH7hUFkzOjV4ME[yOy=>
SNB19 NVHUe214T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrldVgyODBizszN Ml\LOFghcA>? MVfEUXNQ M{n1N2dKPTR;MUCg{txO NFj4dmMzOjV4ME[yOy=>
SW620 NFqwfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:yZ3c3OTByIN88US=> MX60PEBp NGHzNGRFVVOR MkPqS2k2PT1zLkOg{txO NIjBOVAzOjV4ME[yOy=>
TK10 NVjremJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHnNVAxKM7:TR?= MoHIOFghcA>? MmLDSG1UVw>? NFe2cXVIUTV4PU[uN{DPxE1? MXGyNlU3ODZ{Nx?=
UACC257 NHj0Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S5VlExOCEQvF2= NETqU|Y1QCCq MoWzSG1UVw>? M4DVcGdKPTd;NDFOwG0> M1\1PVIzPTZyNkK3
HAEC M{ewTmN6fG:2b4jpZ{BCe3OjeR?= MnnWNVAxKM7:TR?= NUXCTmJvPzJiaB?= NV\DT2FiTE2VTx?= Mne2R5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BJSUWFIIfpeIghUUN3MDDv[kAxNjFizszN NEP3VpIzOzF|MUW0NS=>
HT-29 MYDDfZRwfG:6aXOgRZN{[Xl? M2O3[|ExOCEQvF2= NH3wbHM4OiCq MlPnSG1UVw>? MnXkR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? M4LGd|I{OTNzNUSx
HCT116 NIjIcm9HfW6ldHnvckBCe3OjeR?= MYKyOEBp M1\jRmROW09? M2ryVWFvfGmvaXfyZZRwenliYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJI1q\3KjdHnvci=> Mk\QNlMyPTN{MEC=
HUVEC M{PJ[WZ2dmO2aX;uJGF{e2G7 MlHCNkDPxE1? NFjtfIMyQCCq NUPMWYpMTE2VTx?= M{HYcmFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFczD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;u M4C4Z|I{OTV|MkCw
ACHN Ml6zR5l1d3SxeHnjJGF{e2G7 MVO2JIQ> NEfrWoZKSzVyPUKuOUDPxE1? NFLMPZUzOzN4MEGwOC=>
A498 MnniR5l1d3SxeHnjJGF{e2G7 NI\ZU3YyODBizszN NWrJSlhUPzJiaB?= NF6y[YFFVVOR NH7i[41KSzVyPUSuN{DPxE1? NUOyOYw4OjN2OEm2NlY>
HUVEC NYrWfVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvUbngzOyEQvF2= M3r1bVI1KGh? MmPISG1UVw>? NWXUcGZZSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhfHWkZTDmc5Ju[XSrb36ge4l1cCCHQ{WwJI9nKDBwNkS1JO69VQ>? NYL0NVl5OjN3OEO5NVE>
HUVEC NU\JfFNSU2mwYYPlJGF{e2G7 MYCyNFAh|ryP NHPNXlBFVVOR NGixRVhKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD M4nK[lI{PTh|OUGx
HUVEC MnTET4lv[XOnIFHzd4F6 NUHxd4xnOjByIN88US=> NIfsNZFFVVOR M3PySWlvcGmkaYTpc44hd2ZiVlXHSnIyKHCqb4PwbI9zgWyjdHnvckBqdiCpcn;3eIgh\mGldH;yMZN1cW23bHH0[YQhUFWYRVO= NXPMb4pjOjN3OEO5NVE>
A549 MlvTR5l1d3SxeHnjJGF{e2G7 NGDMXG04OiCq NHLJendFVVOR NFj0fGlKSzVyPUKuOFQh|ryP MmP6NlM3ODJ2NEG=
HCT116 NWe5cIhSS3m2b4TvfIlkKEG|c3H5 NIDZVnM4OiCq MmC3SG1UVw>? NXzoWphPUUN3ME20MlcyKM7:TR?= Mki5NlM3ODJ2NEG=
MCF7 NVLTNINrS3m2b4TvfIlkKEG|c3H5 MVq3NkBp M1vwSWROW09? M363[GlEPTB;Nj6yPUDPxE1? NUPLdJk6OjN4MEK0OFE>
BGC MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPBO|IhcA>? MV3EUXNQ M371TWlEPTB;ND63PEDPxE1? MoPwNlM6QTlyNEC=
BxPC3 M2nTXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG3NkBp M1e3emROW09? MYrJR|UxRTNwNkOg{txO NHW0THczOzl7OUC0NC=>
HT-29 M17r[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDLTmdDPzJiaB?= M{\KPGROW09? NFfie49KSzVyPUGuOFch|ryP MkTWNlM6QTlyNEC=
T24 M3XKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG5[WE4OiCq NIPPV5dFVVOR NGLjbmZKSzVyPUKuOFQh|ryP M33afVI{QTl7MESw
4T1 NEnpd4hEgXSxdH;4bYMhSXO|YYm= NX;Xc|M4PzJiaB?= NGK0OmhFVVOR MmDrTWM2OD1yLkCxOkDPxE1? M3zTc|I1QDlyNkWy
MCF7 M4fCfWN6fG:2b4jpZ{BCe3OjeR?= MYi3NkBp NUjn[2xZTE2VTx?= MljtTWM2OD1yLkCyO|Eh|ryP Mn23NlQ5QTB4NUK=
MCF7 NVTzTIllS3m2b4TvfIlkKEG|c3H5 MlPsO|IhcA>? MoPzSG1UVw>? NHTR[m1KSzVyPUCuNFI6OyEQvF2= M4DLZlI1QDlyNkWy
MDA-MB-231 NHnxS|FEgXSxdH;4bYMhSXO|YYm= NH[zeYg4OiCq MnflSG1UVw>? NVTIfo9IUUN3ME2wMlAzOjNizszN M{L0WFI1QDlyNkWy
MDA-MB-435 NFTubW5EgXSxdH;4bYMhSXO|YYm= MV63NkBp NID0PWtFVVOR NV65[lVVUUN3ME2wMlAxQTdizszN NWPKTZB[OjR6OUC2OVI>
MDA-MB-468 MlXIR5l1d3SxeHnjJGF{e2G7 NF\hTFc4OiCq MljuSG1UVw>? M2XTemlEPTB;MD6wNFYyKM7:TR?= NHrYWIEzPDh7ME[1Ni=>
A431 MV7LbY5ie2ViQYPzZZk> M3npbFExKM7:TR?= NUjaVIZkOSCq NV;XNpNkTE2VTx?= NXLtR41pUW6qaXLpeIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlE4OjFizszN MnL1NlQ5QTB4NUK=
SH-SY5Y NXf1NFJ1U2mwYYPlJGF{e2G7 NEL0S|EyOCEQvF2= NV65d3BMOSCq NVX5[ZZ5TE2VTx?= NF;DeGtKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD3bZRpKEmFNUCgc4YhOC5yOEOxJO69VQ>? NHzoboUzPDh7ME[1Ni=>
U251 MmHhT4lv[XOnIFHzd4F6 NHjPR3EyOCEQvF2= Mn71NUBp NETsO3lFVVOR Mn36TY5pcWKrdHnvckBw\iCYRVfGVlIhf2m2aDDJR|UxKG:oIECuNFE5QSEQvF2= MYSyOFg6ODZ3Mh?=
Bel7402 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[0O|IhcA>? M2KyOWROW09? MYjJR|UxRTJwNkeg{txO M2[4S|I1QTB2OU[x
HK2 NE\FO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm1WmszPzJiaB?= NUfLcZU{TE2VTx?= Ml;wTWM2OD13Lki1JO69VQ>? NVz6OVNtOjR7MES5OlE>
LO2 MoC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2zO|IhcA>? NGn0d5VFVVOR MYTJR|UxRTF7LkmzJO69VQ>? NXPoXXBXOjR7MES5OlE>
MV4-11 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWyR5o1QCCq NWj6bYxrTE2VTx?= M1\6cWlEPTB;MD6wNFMh|ryP MVGyOFkxPDl4MR?=
NCI-H3122 NH[0SFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO4bYlCPzJiaB?= M4rGd2ROW09? NWfibG1pUUN3ME2wMlg{KM7:TR?= Mn;1NlQ6ODR7NkG=
NCI-H460 NGXwNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4V5I4OiCq MofESG1UVw>? Mn7ZTWM2OD12LkOxJO69VQ>? MnfUNlQ6ODR7NkG=
NCI-H526 NFjDWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOyflVyPzJiaB?= NH\QbmtFVVOR NH\BZ5dKSzVyPUGuNFEh|ryP MV2yOFkxPDl4MR?=
TT NET5SopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjUO|IhcA>? NGX5U|lFVVOR M2jUPWlEPTB;MD6wOEDPxE1? M3;t[VI1QTB2OU[x
EoL-1-cell MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDe4NMUUN3ME2xMlY1KHCP NFLKfYxUSU6JRWK=
MV-4-11 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rhSWlEPTB;MkeyJJBO MV\TRW5ITVJ?
NOS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\5TWM2OD1zNT6zJI5O NG\US2xUSU6JRWK=
CGTH-W-1 NIr4eVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPITWM2OD1|MD65OEBvVQ>? NFfxe3BUSU6JRWK=
MONO-MAC-6 NVf4[pYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{C4W2lEPTB;M{OuPEBvVQ>? NFHWUo1USU6JRWK=
ALL-PO M4fVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnaTWM2OD15OT64PUBvVQ>? NHLj[FVUSU6JRWK=
NKM-1 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XNO2lEPTB;OUiuOVIhdk1? NHG0bnBUSU6JRWK=
KM12 NFzkVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XhNWlEPTB;M{WwMlE1KG6P NGL2clhUSU6JRWK=
TE-15 M4LVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\6TWM2OD13MEeuOlEhdk1? M1PyOHNCVkeHUh?=
697 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTZzND6yOUBvVQ>? M2Lmc3NCVkeHUh?=
MOLT-16 Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonGTWM2OD14M{GuN|Ihdk1? NYS5b2tIW0GQR1XS
GB-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTdzMD6yN{BvVQ>? NVW5eXdGW0GQR1XS
TE-12 NXfZRZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonNTWM2OD16MESuOVUhdk1? MUXTRW5ITVJ?
ES6 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;RTWM2OD17OEGuNFYhdk1? MWTTRW5ITVJ?
LC-2-ad MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwMUG0NFch|ryP NU\QXGZjW0GQR1XS
BL-70 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjpTWM2OD1zLkGxPFQ3KM7:TR?= NH24SHNUSU6JRWK=
ETK-1 NIO5R4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPyVZVMUUN3ME2xMlI5PThizszN Mk\GV2FPT0WU
A4-Fuk M3XDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPONYxKSzVyPUGuN|QyPDFizszN NEjCNFFUSU6JRWK=
OCI-AML2 NULyXWV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwM{[4OVEh|ryP NV7JbpBSW0GQR1XS
SIG-M5 NXu3cVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD1zLkO3NFA6KM7:TR?= NFWzO2lUSU6JRWK=
NCI-SNU-16 NUH3U4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HyTGlEPTB;MT60OlQ5PiEQvF2= NVzsSHQxW0GQR1XS
PSN1 NGLsXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLtR4FDUUN3ME2xMlUxPjd4IN88US=> MnWwV2FPT0WU
SR MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GzUmlEPTB;MT61OFU4OiEQvF2= NFfLN5lUSU6JRWK=
A3-KAW MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2[nhKSzVyPUGuOlI2PDZizszN MmXNV2FPT0WU
KS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH0NGhMUUN3ME2xMlY6OjR5IN88US=> M{HSbXNCVkeHUh?=
CTV-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3EUJdKSzVyPUGuO|I4PTFizszN NVvPR2E2W0GQR1XS
LB1047-RCC NU\ZZ4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vyVmlEPTB;MT64NVYzPCEQvF2= NYfGRlI5W0GQR1XS
EMG-01 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJfmlEPTB;MT64N|U3OyEQvF2= NEX3eJBUSU6JRWK=
TE-11 NEjtdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwOEO5PFUh|ryP M3i2SHNCVkeHUh?=
CMK Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\iTWM2OD1zLkm1OVE4KM7:TR?= MWrTRW5ITVJ?
NB1 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyzTWM2OD1zLkm2NVE4KM7:TR?= Mk\LV2FPT0WU
HAL-01 M1T3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW4fFAyUUN3ME2yMlA2QTR4IN88US=> MVnTRW5ITVJ?
DEL MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwMEi0PFIh|ryP NHizXHJUSU6JRWK=
RL95-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwMUGxN|ch|ryP NFj6PXRUSU6JRWK=
KARPAS-299 NYmwSFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD1{LkGxN|E{KM7:TR?= MnX2V2FPT0WU
EW-16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;STmlEPTB;Mj6xN|UxQCEQvF2= MonjV2FPT0WU
RS4-11 NYTZbmVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13x[mlEPTB;Mj6xO|kzPCEQvF2= MmS5V2FPT0WU
BB30-HNC MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwMkKzO|Uh|ryP NFrUVWdUSU6JRWK=
DOHH-2 NVjSZmRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXndVVPUUN3ME2yMlM{PDNzIN88US=> NWnpS5E3W0GQR1XS
RPMI-8402 NVTGeWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLBTWM2OD1{LkOzOlE5KM7:TR?= NYnJXFlyW0GQR1XS
BV-173 NETL[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QVWlEPTB;Mj6zN|Y3KM7:TR?= MoHLV2FPT0WU
TE-10 NX;G[pFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYniWGZVUUN3ME2yMlM1Ozh2IN88US=> NX;3TZpxW0GQR1XS
TE-8 NEfX[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r5eWlEPTB;Mj6zO|A{QCEQvF2= NWCwZ2h6W0GQR1XS
K052 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4Nm1VUUN3ME2yMlQxOjB{IN88US=> MWHTRW5ITVJ?
KARPAS-45 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwNEm0OFYh|ryP M1jreHNCVkeHUh?=
SK-NEP-1 M4HsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;1UmVKSzVyPUKuOlAzOzdizszN MUXTRW5ITVJ?
KGN NXvvOpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nIRWlEPTB;Mj62NFM{QSEQvF2= MV\TRW5ITVJ?
ML-2 M2W0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK1TWM2OD1{Lk[zOVEzKM7:TR?= M4\VPXNCVkeHUh?=
LAMA-84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKT2lEPTB;Mj62PVU1PSEQvF2= MWjTRW5ITVJ?
LXF-289 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvETWM2OD1{LkeyPVg6KM7:TR?= NFfnOWhUSU6JRWK=
A101D NFn6W5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHIZmdKSzVyPUKuO|g{ODRizszN M2L0b3NCVkeHUh?=
KY821 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwN{m3OVgh|ryP NVfqRmRvW0GQR1XS
ES4 NWDYOJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\l[2lEPTB;Mj64NFYzQCEQvF2= NIDC[XZUSU6JRWK=
SCC-3 NXnxR2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPUTWM2OD1{LkiyPFkyKM7:TR?= MkS2V2FPT0WU
NALM-6 NUXzbYpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfKTWM2OD1{LkmwOFc{KM7:TR?= MUDTRW5ITVJ?
BL-41 NWLjNmhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:0TWM2OD1{LkmxNlIzKM7:TR?= NIjTN2VUSU6JRWK=
OPM-2 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXkeppKSzVyPUOuNFU6PTRizszN NYTZOZQ5W0GQR1XS
SF126 NXn2THA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXOTJNuUUN3ME2zMlA3OTl6IN88US=> M4HpdXNCVkeHUh?=
BE-13 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W3SWlEPTB;Mz6yN|EyOSEQvF2= M{P5WnNCVkeHUh?=
SF268 NWXEfoFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLHfZlKSzVyPUOuN|I5PjlizszN MYPTRW5ITVJ?
MOLT-4 NE\4eHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHvTWM2OD1|LkO5PFM5KM7:TR?= MkXPV2FPT0WU
PF-382 NGPYbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrMZnVKSzVyPUOuOFQ2PyEQvF2= M2jtbXNCVkeHUh?=
HEL NHHRWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqyVpNKSzVyPUOuOFgxODVizszN MXvTRW5ITVJ?
RPMI-6666 M1PibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwNUSxO|Eh|ryP NVnuWWhRW0GQR1XS
QIMR-WIL M{CzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzWUoZKSzVyPUOuOlM{QTFizszN MlrzV2FPT0WU
ATN-1 Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTJWYFKSzVyPUOuOlcyOTRizszN M1jKUnNCVkeHUh?=
BB49-HNC NFTWfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13qeWlEPTB;Mz63NFUxQCEQvF2= MWDTRW5ITVJ?
HCE-4 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKwZnhIUUN3ME2zMlc5PjR{IN88US=> MkTpV2FPT0WU
SK-LMS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny3TWM2OD1|LkizN|M5KM7:TR?= Mn;XV2FPT0WU
MS-1 NFq4c5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNwOEO3O|gh|ryP MVHTRW5ITVJ?
JAR NH\JZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vFb2lEPTB;Mz65PFg{OiEQvF2= NH34RVdUSU6JRWK=
KE-37 NXTKPZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme5TWM2OD12LkC2NVU5KM7:TR?= MVLTRW5ITVJ?
LB996-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwMUKxOlgh|ryP MWLTRW5ITVJ?
HH MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;2fIoyUUN3ME20MlIxQTF2IN88US=> NXrKVGRUW0GQR1XS
HL-60 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfJd5J1UUN3ME20MlIyODZ3IN88US=> MXfTRW5ITVJ?
HOP-62 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPvfIt1UUN3ME20MlM{PTJizszN MorlV2FPT0WU
NOMO-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwM{O2PVkh|ryP NUT1VpFLW0GQR1XS
DU-4475 M1H3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHkR3ZKSzVyPUSuN|Y4OjlizszN NGnpZohUSU6JRWK=
LC4-1 NXnEfopDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTRwM{iwO{DPxE1? NUXQbXBNW0GQR1XS
MC116 NVTrZZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDHXIhKSzVyPUSuOFMxQDFizszN NVvRZ|h7W0GQR1XS
SW982 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorzTWM2OD12LkW1N|A4KM7:TR?= MVHTRW5ITVJ?
SK-N-DZ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vteWlEPTB;ND62O|A6QSEQvF2= NWThUo8yW0GQR1XS
EW-1 M1LGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfte4lKSzVyPUSuOlc6OTFizszN M3z1UXNCVkeHUh?=
SU-DHL-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwOECxO|Qh|ryP M2HsWXNCVkeHUh?=
L-363 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwOEC2NlEh|ryP MlfsV2FPT0WU
OS-RC-2 NEPOe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rpemlEPTB;ND64O|MyKM7:TR?= MUTTRW5ITVJ?
HD-MY-Z M2njZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HQOGlEPTB;NT6xO|MxOSEQvF2= NETXN3NUSU6JRWK=
MHH-PREB-1 NWi2VpljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qwXWlEPTB;NT6zNlMyOiEQvF2= M1fVbXNCVkeHUh?=
HC-1 NEjST|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW2TWM2OD13LkSzNlkyKM7:TR?= M4PUXnNCVkeHUh?=
SK-MM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nm[mlEPTB;NT60O|gzKM7:TR?= NI\teVdUSU6JRWK=
SH-4 NV7WcJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DN[WlEPTB;NT60PFM4KM7:TR?= MWPTRW5ITVJ?
MHH-CALL-2 NX2xU3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVwN{[3NVkh|ryP NVruRY5pW0GQR1XS
KG-1 M2\pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGS2lEPTB;Nj6wNlg4QCEQvF2= Mkf3V2FPT0WU
J-RT3-T3-5 NYXnOHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjOTWM2OD14LkC3PVA6KM7:TR?= MVrTRW5ITVJ?
MMAC-SF NHXlN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwMUC5OFkh|ryP NWPqZo1sW0GQR1XS
IST-SL2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\JdZBKSzVyPU[uNVI2OTlizszN NET1NVZUSU6JRWK=
SW954 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\kVXBKSzVyPU[uNlc2OTdizszN Ml\qV2FPT0WU
HDLM-2 NEnJ[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHXfY5uUUN3ME22MlMzOTB7IN88US=> NGXVeJNUSU6JRWK=
ST486 NV3wNm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPNb481UUN3ME22MlM1PzFizszN MV3TRW5ITVJ?
DG-75 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwNEOwOlkh|ryP MnOxV2FPT0WU
EW-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOzTWM2OD14LkSzNlA4KM7:TR?= NUPxTXFCW0GQR1XS
8-MG-BA NYnLOlBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXaTWM2OD14LkWxOVA4KM7:TR?= MmCxV2FPT0WU
GT3TKB NIC5SnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfYTWM2OD14Lk[wO|Y{KM7:TR?= M1\nSXNCVkeHUh?=
KU812 M3yzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzmTWM2OD14Lk[5OFIh|ryP MX\TRW5ITVJ?
CESS NUL6XVVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHKTWM2OD15LkGwOFM5KM7:TR?= NUDvWld6W0GQR1XS
BC-1 NWntOGlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD5TWM2OD15LkK0PFEzKM7:TR?= MYnTRW5ITVJ?
MZ1-PC MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLTbGJXUUN3ME23MlMxOzh7IN88US=> NIfR[JZUSU6JRWK=
NCI-H82 M3LlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjBPId5UUN3ME23MlM4QDVizszN NXXWZml2W0GQR1XS
NCI-H1355 NIWwRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLPU2I1UUN3ME23MlQ2QDB2IN88US=> M1\aVXNCVkeHUh?=
RPMI-8226 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLNTWM2OD15LkWwO|M6KM7:TR?= MmTVV2FPT0WU
ARH-77 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLIVVlKSzVyPUeuOVM2QTdizszN MnzUV2FPT0WU
MN-60 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6SGpKSzVyPUeuOVQxQDhizszN M4GyRXNCVkeHUh?=
IMR-5 MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLFTWM2OD15MEW0PFc3KM7:TR?= NETYTGhUSU6JRWK=
KARPAS-422 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0cGlEPTB;Nz61O|IxPiEQvF2= MWfTRW5ITVJ?
CA46 NXjJTnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[0TWM2OD15LkW4NFEzKM7:TR?= NYO0Nm1iW0GQR1XS
SJSA-1 M4O1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M174SGlEPTB;Nz62OlA3OSEQvF2= MX\TRW5ITVJ?
no-11 NF7MSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTdwN{e1OVch|ryP M1:3UXNCVkeHUh?=
IST-SL1 M3rXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfrd4NDUUN3ME24MlAzPDF5IN88US=> M4rROHNCVkeHUh?=
NCI-H209 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCPWVxUUN3ME24MlEyPjV{IN88US=> MVzTRW5ITVJ?
TALL-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;vTWM2OD16LkG4N|g1KM7:TR?= M4rFWHNCVkeHUh?=
KMOE-2 NY\IZmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDK[Y1KSzVyPUiuNVk1OiEQvF2= MYjTRW5ITVJ?
HCC1599 NGPCPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LH[mlEPTB;OD6xPVk5PyEQvF2= NYH0fZBGW0GQR1XS
CI-1 M2T6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvmRYdCUUN3ME24MlIxPDFzIN88US=> MoHsV2FPT0WU
NCI-H1304 NEex[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqyTWM2OD16LkKwOlYyKM7:TR?= M2XNd3NCVkeHUh?=
Daudi M{SyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwMkO1OFYh|ryP MojGV2FPT0WU
CPC-N NWTOc5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\BPGtKSzVyPUiuNlkyQTlizszN NVTId4dzW0GQR1XS
MC-CAR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vSZmlEPTB;OD6zN|U5KM7:TR?= NFfvdodUSU6JRWK=
SW872 NETmVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLWXpZwUUN3ME24MlM1PzV6IN88US=> MlXuV2FPT0WU
OVCAR-4 NF;tS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTRO3RKSzVyPUiuOVA{PTFizszN M{LJV3NCVkeHUh?=
OCUB-M NH3G[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXaNFdKSzVyPUiuOVY2ODhizszN Ml;BV2FPT0WU
SK-PN-DW NUHnO5pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TBTWlEPTB;OD62NFk5PSEQvF2= M3u5W3NCVkeHUh?=
NCCIT Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\5VGlEPTB;OD63NVc1PSEQvF2= M3fhTHNCVkeHUh?=
NCI-H1648 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PGW2lEPTB;OT6xN|g{PCEQvF2= NYrwNII2W0GQR1XS
COR-L279 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnISXlEUUN3ME25MlM6ODlizszN MVHTRW5ITVJ?
LS-123 M3myZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK0TWM2OD17Lk[4NVYyKM7:TR?= NX\HOXJ2W0GQR1XS
LP-1 M3nsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P3e2lEPTB;OT63PFA5OyEQvF2= NXz2SldbW0GQR1XS
NB13 NELsZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nNSWlEPTB;OT63PVk6PCEQvF2= NHi4e2RUSU6JRWK=
ONS-76 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwOEGwNVYh|ryP Ml;FV2FPT0WU
VA-ES-BJ MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vt[mlEPTB;OT65PVk{OyEQvF2= NV7ST4IxW0GQR1XS
GR-ST M2rtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\FfJdKSzVyPUGwMlIzODdizszN NGnORnZUSU6JRWK=
ES1 NFjxd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLsbVl5UUN3ME2xNE4zQTh2IN88US=> MXXTRW5ITVJ?
NB14 NHrpXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPKN|VKSzVyPUGwMlkzPzdizszN M3nP[nNCVkeHUh?=
Ramos-2G6-4C10 M4fCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml30TWM2OD1zMT6yOlUh|ryP MlzsV2FPT0WU
RXF393 NEX3ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFzLkS4N|Qh|ryP NWraT4M2W0GQR1XS
NCI-H2107 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFzLkW5PFQh|ryP M1W4TnNCVkeHUh?=
K562 M3:0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\sTWM2OD1zMT64O|AzKM7:TR?= NX;XPZNFW0GQR1XS
LOUCY MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1XmlEPTB;MUGuPVg4PSEQvF2= NHXKXnNUSU6JRWK=
TGBC1TKB MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OwdWlEPTB;MUKuNFAzKM7:TR?= MUnTRW5ITVJ?
COLO-320-HSR NFnMSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF{LkG1OlUh|ryP Mo\NV2FPT0WU
K5 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7vTWM2OD1zMj6yPVg2KM7:TR?= Mk\IV2FPT0WU
BC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjCW2VnUUN3ME2xNk41PjVzIN88US=> M2GxW3NCVkeHUh?=
REH M3zGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TtTmlEPTB;MUKuOlQ6QCEQvF2= NGTlcYlUSU6JRWK=
NEC8 NHPWW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvHTWM2OD1zMj62PFg4KM7:TR?= MYPTRW5ITVJ?
IST-MEL1 NUTrc49GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILOTHhKSzVyPUGyMlg3QTRizszN MULTRW5ITVJ?
NCI-H128 M3nrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPy[IpKSzVyPUGzMlA4OjNizszN NVXiOYlDW0GQR1XS
NCI-H1694 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF|LkGxOFQh|ryP NUewO2t3W0GQR1XS
TGW NEHmfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LXR2lEPTB;MUOuN|I4PiEQvF2= Mlm4V2FPT0WU
NCI-SNU-1 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17CRWlEPTB;MUOuN|Q2KM7:TR?= M1jJTHNCVkeHUh?=
IST-MES1 M3:0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF|Lk[3Nlkh|ryP M4rD[3NCVkeHUh?=
CTB-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkixTWM2OD1zMz63Nlk1KM7:TR?= MWDTRW5ITVJ?
HUTU-80 M4DWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i2bWlEPTB;MUOuO|U4OyEQvF2= MonuV2FPT0WU
LAN-6 NE\mOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF2LkK0OVch|ryP M{DWOHNCVkeHUh?=
KP-N-YS Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojYTWM2OD1zND6yPFk1KM7:TR?= NF\pRmFUSU6JRWK=
CCRF-CEM M{i5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2LkSxOlkh|ryP NIDkXlBUSU6JRWK=
NCI-H1770 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\IWmlEPTB;MUSuOVM3QSEQvF2= MlrRV2FPT0WU
MZ2-MEL M2HZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHDPHpKSzVyPUG1MlIzPTFizszN MU\TRW5ITVJ?
COR-L88 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF4LkCwNVIh|ryP MYfTRW5ITVJ?
LOXIMVI NGC0RWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLOTWM2OD1zNj6yOVYh|ryP MX;TRW5ITVJ?
KALS-1 NV;zTo52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjMcIlUUUN3ME2xOk42QTNzIN88US=> NEjKVWFUSU6JRWK=
D-283MED NXGw[XV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXRTWM2OD1zNj64OFg6KM7:TR?= MnnyV2FPT0WU
NCI-H719 NX3JO49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnWbmVmUUN3ME2xOk46OTZzIN88US=> M3HGVHNCVkeHUh?=
MLMA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF4Lkm5NFch|ryP NInaUHdUSU6JRWK=
EVSA-T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nDbGlEPTB;MUeuNFQ5PSEQvF2= NXvSZ45vW0GQR1XS
SK-N-FI NIOx[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jKTGlEPTB;MUeuOlkyOyEQvF2= MX7TRW5ITVJ?
NTERA-S-cl-D1 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITiSJZKSzVyPUG3Mlg2PzJizszN NH;0WFhUSU6JRWK=
NCI-H1882 M{LFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF5Lkm4N|Qh|ryP MUnTRW5ITVJ?
A704 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjVO21KSzVyPUG3Mlk6ODRizszN NXLXRoVqW0GQR1XS
L-428 NWXMOlV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LqWGlEPTB;MUiuNFE2OSEQvF2= NFi5XZZUSU6JRWK=
HCC1187 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEizU5VKSzVyPUG4MlAyQDdizszN NHi5NlNUSU6JRWK=
NCI-H1581 NUDsbmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK2TWM2OD1zOD6wPFY3KM7:TR?= M2jkUnNCVkeHUh?=
BB65-RCC M3;Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF6LkSxOlIh|ryP NILGNYtUSU6JRWK=
EM-2 NVP1eZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1UmlEPTB;MUiuOVY4OiEQvF2= M3;XPHNCVkeHUh?=
Raji M1THd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;yT2JKSzVyPUG5Mlk2PjVizszN NH;kVHFUSU6JRWK=
TE-1 NH7rcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJyLkSxNFQh|ryP MX7TRW5ITVJ?
SW962 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXmZmlbUUN3ME2yNE41Ojl|IN88US=> MVfTRW5ITVJ?
MHH-NB-11 NEPZ[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLPZnRvUUN3ME2yNE42PTJzIN88US=> MYTTRW5ITVJ?
no-10 NV6xcIxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzRTWM2OD1{MT6wNlY1KM7:TR?= MWLTRW5ITVJ?
GDM-1 NGnJWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TGVWlEPTB;MkGuPVQyPCEQvF2= MVTTRW5ITVJ?
KMS-12-PE NWj2V3kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq0[opRUUN3ME2yNk4zPzRizszN MnPBV2FPT0WU
NCI-H510A M2HnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ2LkGyO|gh|ryP NFLi[3hUSU6JRWK=
ES5 M3X5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ2LkezOFkh|ryP NVzvcHE3W0GQR1XS
JiyoyeP-2003 NHT1SGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ4LkK3OFIh|ryP MX7TRW5ITVJ?
NMC-G1 M4rr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfxVHFxUUN3ME2yO{4yQDJ{IN88US=> NWXTTI9OW0GQR1XS
NCI-H446 NI\a[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XpUWlEPTB;MkeuOFk1PiEQvF2= NYLxXVFOW0GQR1XS
NB7 M1TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u4R2lEPTB;MkeuPVIzQSEQvF2= MUXTRW5ITVJ?
A388 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPqVIZCUUN3ME2yPE4xODd2IN88US=> NI\OZZFUSU6JRWK=
JVM-2 NIXTfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLBWVlKSzVyPUK4MlI5QThizszN M2rFdXNCVkeHUh?=
HT-144 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn3R2ZKSzVyPUK4MlY6KM7:TR?= M4fDVXNCVkeHUh?=
NCI-H747 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXFVIJKSzVyPUK4MlkyQTVizszN NH\CUlBUSU6JRWK=
NCI-H1650 NH7qUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1eyZmlEPTB;MkmuNFE4PiEQvF2= M3fQTHNCVkeHUh?=
EB-3 MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPhTWM2OD1{OT61N|A6KM7:TR?= MofNV2FPT0WU
KLE NGjmTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HXVmlEPTB;MkmuOlE6KM7:TR?= MnPOV2FPT0WU
TK10 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrBOohwUUN3ME2zNE4yOjZizszN M3TLZnNCVkeHUh?=
COLO-668 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jXPWlEPTB;M{CuO|kzKM7:TR?= MlvkV2FPT0WU
NCI-H23 NIPiPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom3TWM2OD1|MT6xNFY{KM7:TR?= MkHvV2FPT0WU
GOTO MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNzLk[wPFUh|ryP NYPYb2JLW0GQR1XS
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTNzLki2O|gh|ryP MYHTRW5ITVJ?
LB831-BLC NXy3Sm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fnfmlEPTB;M{KuN|g1OyEQvF2= NXLJTlVDW0GQR1XS
SCH NIDiNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTTVZBKSzVyPUOyMlg1QDVizszN M2mzNnNCVkeHUh?=
EHEB NVXkV|hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfhTWM2OD1|ND6xNVk{KM7:TR?= NFzwVHFUSU6JRWK=
U-266 NVnidZN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN2LkK3PFEh|ryP M2n4TnNCVkeHUh?=
EW-11 NHTHV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn1UoxKSzVyPUO0MlQ4OjVizszN MXHTRW5ITVJ?
TE-9 M{OzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGzb3luUUN3ME2zO{4xPDBzIN88US=> M3;qS3NCVkeHUh?=
ES3 MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN5LkWwNFQh|ryP MXLTRW5ITVJ?
NCI-H2141 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN6LkC4OFMh|ryP NUHSXmNNW0GQR1XS
MPP-89 NGfsZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HuSWlEPTB;NEKuNFU5PiEQvF2= M2i1VHNCVkeHUh?=
SK-MEL-2 M1PHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCxTWM2OD12Mj62OFA2KM7:TR?= MXvTRW5ITVJ?
LC-1F NVznWYM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR|LkO2PFIh|ryP M4rkcnNCVkeHUh?=
NH-12 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOyTJJKSzVyPUSzMlk{PTlizszN NYXyeXR[W0GQR1XS
RKO M{S1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfWdpRKSzVyPUS0MlEzPTJizszN MlL4V2FPT0WU
KM-H2 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL4TWM2OD12ND65OVc4KM7:TR?= MYXTRW5ITVJ?
SK-UT-1 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrsTWM2OD12OT64PFI2KM7:TR?= MVLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
- Collapse
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01391962 Recruiting Drug: Cediranib|Drug: Sunitinib Sarcoma Alveolar Soft Part National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 19 2011 Phase 2
NCT01073644 Terminated Drug: Sunitinib malate Metastatic Renal Cell Carcinoma Pfizer February 2010 --
NCT00912912 Terminated Drug: Sunitinib Malate Genitourinary Disease M.D. Anderson Cancer Center|Pfizer May 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID